Avalo Therapeutics Inc. (AVTX)
undefined
undefined%
At close: undefined
9.23
0.05%
After-hours Dec 13, 2024, 04:00 PM EST

Avalo Therapeutics Statistics

Share Statistics

Avalo Therapeutics has 10.46M shares outstanding. The number of shares has increased by -52.1% in one year.

Shares Outstanding 10.46M
Shares Change (YoY) n/a
Shares Change (QoQ) 837.99%
Owned by Institutions (%) n/a
Shares Floating 8.40M
Failed to Deliver (FTD) Shares 679
FTD / Avg. Volume 1.39%

Short Selling Information

The latest short interest is 10.06K, so 0.1% of the outstanding shares have been sold short.

Short Interest 10.06K
Short % of Shares Out 0.1%
Short % of Float 0.12%
Short Ratio (days to cover) 0.33

Valuation Ratios

The PE ratio is -0.08 and the forward PE ratio is -2.73.

PE Ratio -0.08
Forward PE -2.73
PS Ratio 1.31
Forward PS 96.5
PB Ratio 0.35
P/FCF Ratio -0.08
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

Avalo Therapeutics Inc. has an Enterprise Value (EV) of -985.68K.

EV / Earnings 0.03
EV / Sales -0.51
EV / EBITDA 0.04
EV / EBIT 0.04
EV / FCF 0.03

Financial Position

The company has a current ratio of 1.82, with a Debt / Equity ratio of 0.

Current Ratio 1.82
Quick Ratio 1.82
Debt / Equity 0
Total Debt / Capitalization 0
Cash Flow / Debt 0
Interest Coverage -6.86

Financial Efficiency

Return on equity (ROE) is -4.32% and return on capital (ROIC) is -299.13%.

Return on Equity (ROE) -4.32%
Return on Assets (ROA) -1.5%
Return on Capital (ROIC) -299.13%
Revenue Per Employee 101.26K
Profits Per Employee -1.66M
Employee Count 19
Asset Turnover 0.09
Inventory Turnover 0

Taxes

Income Tax 14.00K
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by -35.97% in the last 52 weeks. The beta is 1.03, so Avalo Therapeutics 's price volatility has been higher than the market average.

Beta 1.03
52-Week Price Change -35.97%
50-Day Moving Average 11.18
200-Day Moving Average 10.9
Relative Strength Index (RSI) 36.43
Average Volume (20 Days) 48.78K

Income Statement

In the last 12 months, Avalo Therapeutics had revenue of $1.92M and earned -$31.54M in profits. Earnings per share was $-113.58.

Revenue 1.92M
Gross Profit 640.00K
Operating Income -23.44M
Net Income -31.54M
EBITDA -27.95M
EBIT -23.44M
Earnings Per Share (EPS) -113.58
Full Income Statement

Balance Sheet

The company has $7.42M in cash and $537.00K in debt, giving a net cash position of $6.88M.

Cash & Cash Equivalents 7.42M
Total Debt 537.00K
Net Cash 6.88M
Retained Earnings -335.13M
Total Assets 98.45M
Working Capital 25.47M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$30.68M and capital expenditures -$158.00K, giving a free cash flow of -$30.84M.

Operating Cash Flow -30.68M
Capital Expenditures -158.00K
Free Cash Flow -30.84M
FCF Per Share -111.04
Full Cash Flow Statement

Margins

Gross margin is 33.26%, with operating and profit margins of -1.22K% and -1.64K%.

Gross Margin 33.26%
Operating Margin -1.22K%
Pretax Margin -1.64K%
Profit Margin -1.64K%
EBITDA Margin -1.45K%
EBIT Margin -1.22K%
FCF Margin -1.60K%

Dividends & Yields

AVTX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -1231.89%
FCF Yield -31.95%
Dividend Details

Analyst Forecast

The average price target for AVTX is $35, which is 279.6% higher than the current price. The consensus rating is "Hold".

Price Target $35
Price Target Difference 279.6%
Analyst Consensus Hold
Analyst Count 2
Stock Forecasts

Stock Splits

The last stock split was on Dec 29, 2023. It was a backward split with a ratio of 1:240.

Last Split Date Dec 29, 2023
Split Type backward
Split Ratio 1:240

Scores

Altman Z-Score -4.91
Piotroski F-Score 1